CompletedNot Applicable

Predicting Heart Failure Outcomes With Biomarkers and Imaging

4,000 participantsStarted 2012-01-01

Plain-language summary

This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features like epicardial fat density) improves risk prediction compared to using either type of data alone. This is a retrospective study using existing medical records of patients treated for chronic heart failure at Xinjiang Medical University First Affiliated Hospital between 2012 and 2024. No new patient contact or interventions are involved. The goal is to enable more accurate, personalized risk assessment across different types of heart failure (HFrEF, HFmrEF, HFpEF).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years.
✓. Confirmed diagnosis of chronic heart failure.
✓. Treated at the study center between January 1, 2012, and December 31, 2024.
✓. Availability of both qualifying blood biomarker test results (NT-proBNP and/or high-sensitivity cardiac troponin) and cardiac imaging (echocardiography and/or cardiac CT) performed within a ±3-month window around the index encounter.

Exclusion criteria

✕. Heart failure primarily due to severe primary valvular disease, acute myocardial infarction, myocarditis, or pulmonary embolism.
✕. End-stage renal disease requiring dialysis.
✕. Clinical records or follow-up data are severely incomplete, precluding outcome assessment.

What they're measuring

All-cause mortality

Timeframe: 1 year

Trial details

NCT IDNCT07332520

SponsorXinjiang Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Heart Failure trials